MedTrace Logo

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

NCT05295394 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-04-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients with a documented M184V mutation.

Conditions

  • HIV-1 Infection

Interventions

DRUG

Dolutegravir plus lamivudine

Dolutegravir 50 mg QD plus lamivudine 300 mg QD

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Pedro Cahn

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-22
Primary Completion
2022-08-31
Completion
2022-08-30

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295394 on ClinicalTrials.gov